Opus Genetics, Inc
Clinical trials sponsored by Opus Genetics, Inc, explained in plain language.
-
Gene therapy injection aims to halt rare blindness diseases
Disease control Recruiting nowThis early-stage trial tests a gene therapy called OPGx-BEST1 for two rare inherited eye conditions that cause vision loss. About 10 adults with either Best vitelliform macular dystrophy or autosomal-recessive bestrophinopathy will receive a single injection under the retina in o…
Phase: PHASE1, PHASE2 • Sponsor: Opus Genetics, Inc • Aim: Disease control
Last updated May 17, 2026 11:02 UTC
-
Experimental gene injection aims to halt rare blindness in kids and adults
Disease control Recruiting nowThis study tests a gene therapy called OPGx-001 for people with vision loss caused by changes in the LCA5 gene. The treatment is a one-time injection under the retina. The main goals are to check safety and see if it can slow or stop vision from getting worse. The study includes …
Phase: PHASE1, PHASE2 • Sponsor: Opus Genetics, Inc • Aim: Disease control
Last updated May 11, 2026 20:47 UTC